Virax Biolabs Group (NASDAQ:VRAX) Trading Down 4.2%

Virax Biolabs Group Limited (NASDAQ:VRAX – Get Rating) traded down 4.2% on Thursday . The stock traded as low as $0.74 and last traded at $0.75. 268,711 shares were traded during trading, a decline of 85% from the average session volume of 1,768,509 shares. The stock had previously closed at $0.78.

Virax Biolabs Group Stock Performance

The firm has a 50-day moving average of $0.79 and a two-hundred day moving average of $1.51.

Hedge Funds Weigh In On Virax Biolabs Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS Group AG bought a new stake in shares of Virax Biolabs Group in the 3rd quarter valued at approximately $38,000. Legal & General Group Plc bought a new stake in Virax Biolabs Group during the 4th quarter worth approximately $73,000. Finally, Virtu Financial LLC bought a new stake in Virax Biolabs Group during the 4th quarter worth approximately $35,000. 0.46% of the stock is currently owned by institutional investors.

About Virax Biolabs Group

(Get Rating)

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products.